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Whereas, within normal murine and human epidermis, the expression of class 
II alloantigens  is restricted  to bone marrow-derived  Langerhans  cells (LC) (1), 
several investigators have recently reported on the detection of class II alioanti- 
gens  on  keratinocytes  (KC)  in  certain  disease  states,  e.g.  cutaneous  T  cell 
lymphoma (CTCL) (2), lichen planus (LP) (2), and cutaneous graft-vs.-host disease 
(GVHD) (3).  The emergence of HLA-DR antigens on primarily DR- KC raises 
the  question  about  their  cellular  origin.  The  possibility  that  they  might  be 
synthesized,  rather  than  passively acquired,  gains  support  from animal  studies 
showing that induction of GVHD in irradiated Ft hybrid rodents by the injection 
of parental  lymphocytes results  in  the  appearance  of KC  Ia  antigens  of host 
phenotype (4, 5).  Due to careful HLA-matching,  in human bone marrow trans- 
plantation  hapiotypic  differences  or  identities  between  KC-bound  and  donor 
cell-derived Ia antigens cannot be evaluated. Our strategy to clarify the cellular 
origin of la antigens on human  KC was therefore based on different considera- 
tions.  HLA-DR antigens represent the human analogue to murine  I-E antigens 
(6), whereas HLA-DS (7) or DC 1 antigens (8) correspond to murine  I-A mole- 
cules.  HLA-DR oligomers are formed by the noncovalent association of three 
po]ypeptides,  i.e.,  a,  /3,  and  3'  chains  (9).  As opposed to  a  and/3  chains  the  3' 
chain appears to be invariant,  at least by charge and mass, regardless of the DR 
phenotype (10,  11). Cell surface HLA-DR molecules consist only of a//3-dimers, 
whereas  3'  chains  appear  to be part  of HLA-DR oligomers  exclusively during 
cytoplasmic processing (12) and are apparently needed for the intracytoplasmic 
transport  of HLA-DR (9).  We thus  felt that  demonstration  of the  HLA-DR 3" 
chain  within  a  cell  carrying  HLA-DR a  and/3  surface moieties would provide 
strong evidence for active HLA-DR biosynthesis by this given cell. 
The  monoclonal  antibody  VIC-Y1  (13)  defines  an  antigenic  determinant 
carried exclusively by cytoplasmic HLA-DR 3" chains, both free and in association 
with HLA-DR c~ and/3 oligomers (14). We now describe the occurrence of HLA- 
DR antigens on KC in disease states and demonstrate that KC carrying surface- 
bound HLA-DR antigens exhibit cytoplasmic staining when exposed to VIC-Y1 
in  an  indirect  immunofluorescent  (IF)  technique.  We  therefore  propose  that 
HLA-DR antigens on KC of diseased skin are actively synthesized by these cells. 
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TABLE  I 
Monoclonal Antibodies 
Monoclonal  IgG Class  Antigenic  Working 
antibody  determinant  dilutions 
Anti-HLA-DR (15) (Becton/  IgGh  Nonpolymorphic determi-  1:40 
Dickinson (BD)) unconju-  nants  on the DR a/0 com- 
gated, FITC- or TRITC-  plex 
labeled 
VIC-Y1 (13, 14)  IgGl  Cytoplasmic DR 3' chain  1:10 
Anti-Leu-10 (16) (BD)  IgGl  a/0 chains of non-HLA-DR  1:5 
molecules co-migrating 
with DC-1 molecules 
OKT6 (17) (Ortho Diagnos-  IgGl  T6 antigen (cortical thymo-  1:10 
tic Systems Inc., Raritan,  cytes, epidermal LC) 
Nj) 
Material and Methods 
Biopsy Specimens.  Excisional biopsies were obtained from lesional skin of patients with 
LP  (13  cases),  CTCL (6  cases),  and  chronic cutaneous GVHD  (5  cases),  which  had 
developed after allogeneic bone marrow transplantation. Skin specimens from patients 
undergoing corrective plastic  surgery served as control. The tissues were embedded in 
OCT compound (Tissue Tek, Ames Co., Elkhart, IN), snap-frozen in isopentane cooled 
in liquid nitrogen and stored at -70°C. 
Monoclonal Antibodies.  (See Table I.) Binding of unconjugated monoclonal antibodies 
was  visualized  by affinity-purified fluorescein" isothiocyanate (FITC) goat F(ab')2  anti- 
mouse IgG (Tago Inc., Burlingame, CA; working dilution 1:10 in PBS). 
Immunofluorescence.  4-#m  cryostat skin  sections were  air-dried,  acetone-fixed, and 
rinsed in phosphate-buffered saline (PBS), pH 7.2.  For direct IF studies, sections were 
incubated with either FITC- or tetra-methyl-rhodamine isothiocyanate (TRITC)-labeled 
anti-HLA-DR for 30 rain. In indirect IF assays, sections were first exposed to appropriate 
dilutions  of anti-HLA-DR,  anti-Leu-10,  VIC-Y1,  OKT6  monoclonai antibodies,  or 
nonimmune ascites  as  a  control,  and  antibody binding  was  visualized  by  a  30-min 
incubation with FITC goat F(ab')2 anti-mouse IgG. When double-labeling was attempted, 
the sections were incubated with 20%  normal mouse serum, washed, and then exposed 
to  appropriate  dilutions of TRITC-anti-HLA-DR (30  min).  After final  PBS  washes, 
sections were air-dried, mounted with FA mounting fluid (Difco Labs, Detroit, MI), and 
examined under a Leitz Ortholux fluorescent microscope. 
Results 
Normal Human Skin.  Despite differences in binding patterns within the der- 
mis, the epidermal  reactivity of all monoclonal reagents (anti-HLA-DR, anti- 
Leu-10, OKT6, VIC-Y 1 [Fig. 1  ]) is restricted to dendritic cells whose shape and 
distribution identify them as LC and indeterminate cells, respectively. 
Diseased Skin.  Compared to the frequency of OKT6+/HLA-DR+/HLA-DS+/ 
VIC-Y1 ÷ LC and indeterminate cells within normal epidermis, their number was 
slightly increased in LP and CTCL specimens but appeared decreased in GVHD 
epidermis. The most conspicuous feature in sections of 12/13  LP, 5/6 CTCL, 
and  5/5  GVHD  patients  was  the  emergence  of HLA-DR antigens  on  KC  of 
virtually all  layers  of the  epidermis.  The  uniform  membrane  staining of KC 
exposed to anti-HLA-DR was contrasted by their lack of reactivity with anti- 
Leu-10 (Fig. 2, a  and b). In LP and CTCL biopsies, expression of surface HLA- 
DR was most pronounced on KC overlying dense mononuclear cell infiltrates, 
whereas in GVHD samples virtually all KC displayed uniform surface staining. 
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FIGURE  1.  Reactivity pattern of VIC-Y1  with normal human skin: cytoplasmic staining of 
dendritic suprabasal LC within the epidermis. FIGURE 2. (a-c)  CTCL, stage IA: staining of 
cryostat sections with (a) TRITC-labeled anti-HLA-DR: distinct surface staining of KC in a 
netlike pattern. Beneath the dermo-epidermaljunction, the infiltrate contains abundant anti- 
HLA-DR  reactive  cells.  (b)  Staining of an adjacent section  with  anti-Leul0:  KC  remain 
negative, while staining of epidermal LC and dermal infiltrating cells can be observed (the 
dashed line indicates the dermal-epidermal  junction). (c) VIC-Y1 in a serial section of the same 
biopsy specimen: cytoplasmic, fluorescence within the majority of KC but no surface staining. 
FIGURE 3.  (a,  b) Surface-bound HLA-DR a//3 complexes (a-arrow; anti-HLA-DR, TRITC) 
and intracytoplasmic HLA-DR "r chain (b-arrow; VIC-Y1, FITC) by double labeling. 
found that, within corresponding areas of the specimens, KC displayed homog- 
enous cytoplasmic fluorescence sparing the nuclear region and the intercellular 
spaces (Fig.  2c).  Double staining procedures revealed that anti-HLA-DR and 
VIC-Y1  reactive antigenic determinants are located on the surface and within 
the cytoplasm, respectively, of the very same KC (Fig. 3, a and b). Controls with 
nonimmune ascites as first-step reagent were completely devoid of staining. 
Discussion 
The  intracytoplasmic  demonstration  of HLA-DR  y  chains  within  the  KC 
bearing surface-bound HLA-DR o~ and/3 chains provides strong evidence for the 
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During HLA-DR  biosynthesis, oligomeric assembly of DR  0t,  /3,  and 7  chains 
occurs shortly after their synthesis in the endoplasmic reticulum as pulse-chase 
experiments have revealed that by immune precipitation with either anti-HLA- 
DR all3 reagent (9) or VIC-Y1  (14), all three polypeptide chains are co-precipi- 
tated. DR 3' chains present in the oligomeric complex with DR a  and/3 moieties 
undergo intracellular transport and, subsequently, are detached from the oligo- 
meric complex that finally appears on the cell surface (9,  14). The ultimate fate 
of the DR 3' chain is unknown. Although Koch et al. (18) recently reported on 
the detection of the murine Ia  invariant chain on  lymphocyte surfaces, most 
authors  agree  that  its  presence  is  restricted  to  the  cytoplasm  (9,  12).  Our 
numerous attempts to detect surface reactivity of VIC-Y1  by immunoelectron 
microscopy and flow cytofluorometry consistently yielded negative results (14). 
We therefore propose that the human DR 7 chain or at least its VIC-Y1 reactive 
portion does not appear on the cell surface and that VIC-Y1 is a selective marker 
for cytoplasmic HLA-DR. The virtually complete correlation of VIC-Y 1 cyto- 
plasmic and anti-HLA-DR surface reactivity again points to the important role 
of 3" chains in HLA-DR biosynthesis. Since, however, the murine invariant chain 
gene is not included in the MHC-complex (19), one may argue by analogy that, 
in the disease states described, yet unknown stimuli may induce KC to synthesize 
DR 3' chains without concomitant induction of DR a/~ synthesis. Such an event 
has recently been  reported with  human and  murine plasmacytoma cells (20). 
Consequently, one would have to concede that KC surface HLA-DR a/t3 chains 
were passively absorbed from surrounding DR-positive cells, which in the course 
of the  respective  disease  process,  either  had  become  severely damaged,  or 
alternatively, had been induced to synthesize excess amount of DR a/t$ chains. 
Although the exchange of Ia determinants between cells has been reported (21), 
we consider this possibility rather unlikely, mainly because of our finding that 
anti-HLA-DR reactive and VIC-Y1  reactive KC were essentially identical. 
When  we thus assume that  KC-bound  surface HLA-DR  in  diseased skin  is 
actively synthesized by these cells, the stimuli leading to this event have yet to be 
clarified. There is ample evidence that Ia antigen expression on murine macro- 
phages can be modulated by soluble factors released by T  cells after antigen or 
mitogen activation.  In this regard, particular attention has focused on 3"-inter- 
feron which--in contrast to other cytokines tested--can induce Ia expression 
on primarily Ia- macrophages (22) and umbilical vein endothelial cells (23). It is 
thus conceivable that,  in  the disease states  listed,  activated T  cells within the 
dermal infiltrate produce quantities of 3"-interferon sufficient to induce HLA- 
DR biosynthesis by KC. 
The appearance of HLA-DR,  but not HLA-DS antigens on primarily DR- 
cells may shed some light on the role of these alloantigens in the induction of T 
cell-dependent immune responses. Normal DR- KC are not capable of inducing 
proliferative T  cell responses (24). The question of whether or not the acquisition 
of DR  moieties by  KC  widens the repertoire of their  functional capacities is 
currently under investigation. 
Summary 
As opposed to normal human skin where HLA-DR expression is restricted to 
the Langerhans cell (LC) population,  HLA-DR, but not HLA-DS antigens can 1788  VOLC-PLATZER ET  AL.  BRIEF  DEFINITIVE REPORT 
be readily detected on keratinocytes (KC) in certain disease states, i.e., cutaneous 
T  cell lymphoma (CTCL), graft-vs-host disease (GVHD), and lichen planus (LP). 
To clarify the cellular origin of KC-bound HLA-DR antigens, we used a  mono- 
clonai antibody directed against determinants solely expressed on the cytoplasmic 
HLA-DR  3'  chain  (VIC-Y1)  and  observed  that,  by  immunofluorescence,  KC 
displaying HLA-DR a/B complexes on  their surface uniformly displayed cyto- 
plasmic VIC-Y1  reactivity. In view of the crucial role of the 3' chain for HLA- 
DR biosynthesis, we conclude that HLA-DR antigens on KC are actively synthe- 
sized by these cells. 
Received  for publication 3January 1984 and in revised  form 13 March 1984. 
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